The same group later showed that an allogeneic tumor vaccine combining transgenic human lymphotactin with IL-2 in patients with advanced and refractory neuroblastoma led to 2-fold expansion of CD4+ T cells and 3.5-fold expansion of NK cells, inducing a more potent immunologic and clinical response. The gene discussed is IL2; the disease is neuroblastoma.